SPOROS MONITORING BRIEF

Watchlist: Eli Lilly & Co · Pfizer Inc · UnitedHealth Group Inc · Goldman Sachs Group Inc Latest record on file: 2026-04-06

TOP LINE

The Department of Labor's Employee Benefits Security Administration has published a proposed exemption that would permit Goldman Sachs-related asset managers to rely on Prohibited Transaction exemptions — a direct, named regulatory action with material consequences for Goldman's institutional asset management business that requires active response before the comment period closes ^[25] (2026-04-02).

WHAT MATTERS

1. Goldman Sachs Group Inc — DOL proposes Prohibited Transaction exemption for Goldman asset managers ^[25] (2026-04-02)

The Federal Register notice (11 pages, FR Doc 2026-06408, Exemption Application No. D-12122) is a formal proposed exemption under ERISA from the Department of Labor's Employee Benefits Security Administration. If granted, it would permit Goldman-related asset managers to rely on Prohibited Transaction exemptions they would otherwise be barred from using — likely stemming from a disqualifying event (conviction, civil settlement, or similar trigger) that stripped Goldman entities of their PT exemption eligibility. This is a named, graph-linked regulatory action directly affecting Goldman's ability to manage ERISA-covered plan assets. Action required: Confirm the disqualifying predicate event; identify which Goldman asset management entities are covered; calendar the public comment deadline; assess whether a comment submission or engagement with EBSA is warranted. Failure to obtain the exemption would impair Goldman's institutional asset management franchise with pension and retirement plan clients.

2. Eli Lilly & Co — Three concurrent FDA Warning Letters to CEO David Ricks re: Zepbound/Mounjaro promotion ^[2][3][4] (2025-09-09)

Records ^[2] and ^[3] are fully extracted; ^[4] is body-unavailable and must be verified directly.

• ^[2]: CDER issued a warning letter (NDA 217806 / NDA 215866; MA 974 and 832) citing a direct-to-consumer video — "An Oprah Special: Shame, Blame, and the Weight Loss Revolution" — featuring two paid Lilly consultants (Dr. W. Scott Butsch, Dr. Amanda Velazquez). FDA's theory is that the video, featuring Lilly representatives, constitutes promotional communication subject to FDA labeling and fair balance requirements.
• ^[3]: A second warning letter (NDA 217806; MA 831) cites a separate online video on dayton247now.com featuring Dr. Clare Lee (Lilly Associate VP, Medical Affairs) and Rhonda Pacheco (Lilly Group VP), identified as Lilly representatives, discussing Zepbound. The use of named senior Lilly executives as interviewees triggers direct attribution.
• ^[4]: Third warning letter, same date, same CEO recipient — body not extractable; verify directly at FDA's warning letter database (CDER). Given the same-day issuance and NDA context, this is almost certainly a third promotional violation on tirzepatide products.

Assessment: Three simultaneous warning letters to the CEO on the company's highest-revenue growth product franchise is a significant enforcement posture. These are ~7 months old but unresolved corrective-action status is unknown — verify whether Lilly has submitted a written response and whether FDA has closed or escalated any of the three matters. Ongoing non-compliance could trigger injunctive action or ad-misbranding referral.

3. Pfizer Inc — FDA initiates regulatory review period determination for HYMPAVZI (patent extension) ^[9] (2026-04-03)

FDA published its determination of the regulatory review period for HYMPAVZI (Pfizer's hemophilia B gene therapy, fitusiran or similar), as required by law, because a patent extension application was filed. This is the formal clock-start for USPTO patent term extension eligibility under Hatch-Waxman. Implication: The length of the review period FDA certifies directly determines whether — and for how long — Pfizer can extend exclusivity. Any challenger or interested party (e.g., generic/biosimilar applicant) has 180 days from publication to submit comments contesting FDA's determination. Monitor for competing comments; this is a near-term exclusivity-defining event.

4. Pfizer Inc — Regulatory review period determination for ORLYNVAH ^[11] (2026-02-26) — [BODY NOT EXTRACTED]

Same mechanism as ^[9] above — FDA Hatch-Waxman patent extension review period determination for ORLYNVAH. Document body not machine-readable. Verification lead: Retrieve directly from Federal Register (FR Doc linked to Docket FDA-2026 series) to confirm the certified review period length and comment deadline. Do not treat as resolved.

5. Eli Lilly & Co — FDA Strattera "not withdrawn for safety" determination clears path for generic ANDA approvals ^[1] (2026-04-06)

FDA determined that STRATTERA (atomoxetine HCl) capsules across all eight approved strengths (5–100 mg) were not withdrawn from sale for reasons of safety or effectiveness (Docket FDA-2025-P-6868). This is a standard but consequential notice: under 21 CFR 314.161, such a determination is a prerequisite for FDA to approve ANDAs (generic applications) referencing the branded NDA. Implication: Generic manufacturers can now receive ANDA approvals for atomoxetine at all strengths. For Lilly, Strattera is a mature, off-patent asset — this accelerates generic competition but is not a surprise. Monitor for any follow-on ANDA approval actions.

6. Goldman Sachs Group Inc — ELEVATED 8-K filing ^[26] (2026-03-13)

Body not extracted. Given the concurrent DOL proposed exemption ^[25], an 8-K filed two weeks later warrants verification — it may contain related disclosures, material agreement announcements, or regulatory update language. Verification lead: Retrieve from SEC EDGAR; confirm whether it references the EBSA matter or is unrelated.

BY WATCHLIST ITEM

Eli Lilly & Co — 773 corpus mentions; 300 LDA lobbying filings reflect a heavy, sustained federal presence. Recent movement is substantive: three simultaneous FDA warning letters to the CEO on its flagship tirzepatide franchise (Sept 2025) ^[2][3][4] remain the dominant enforcement signal, compounded by a Strattera generic pathway clearing this week ^[1]. The KISUNLA patent extension determination (July 2025) ^[8] and an EUA revocation (July 2025) ^[6] round out a period of sustained FDA regulatory activity. One warning letter body is unextracted ^[4] — verify at FDA.

Pfizer Inc — 1,263 corpus mentions; 539 LDA filings represent the largest lobbying footprint on this watchlist by a wide margin, consistent with a company managing an exceptionally broad product and regulatory portfolio. Two Hatch-Waxman patent extension clock-starts (HYMPAVZI ^[9], ORLYNVAH ^[11]) are the live exclusivity events; ^[11] body is unextracted. The 46-NDA mass withdrawal ^[10] involves multiple applicants (Aspen Global et al.) and is likely not a direct Pfizer adverse action — Pfizer's name appears in the docket context; attribution to Pfizer specifically must be confirmed. A 20-ANDA King Pharmaceuticals withdrawal ^[13] (Dec 2025) names Pfizer as U.S. agent — routine housekeeping, low commercial impact.

UnitedHealth Group Inc — 771 corpus mentions; 300 LDA filings and 63 SEC filings reflect a substantial but currently quiet posture in this corpus. Most recent graph-linked record is an 8-K from June 2025 ^[17]; all other retrieved records date to 2024. No high or elevated regulatory action is on file for the current monitoring period. Given UHG's public profile (DOJ antitrust scrutiny, CMS rate-setting, ongoing congressional attention to insurer practices), the absence of a recent enforcement or rulemaking record in this corpus should not be read as "all clear" — it reflects corpus coverage limits, not a clean regulatory environment. Flag for supplemental monitoring via CMS, DOJ, and state insurance commissioner sources.

Goldman Sachs Group Inc — 862 corpus mentions; 239 beneficial-ownership (13D/G) filings and 230 LDA filings reflect both a major institutional investor footprint and sustained federal lobbying. The DOL proposed exemption ^[25] is the live, time-sensitive action item — comment period deadline must be confirmed immediately. The March 2026 8-K ^[26] is an unverified follow-on to track. A Texas Stock Exchange rule filing ^[31] (Dec 2025) involving Goldman's parent company governance documents is an ELEVATED item worth reviewing for structural implications.

*Coverage note: Most recent record on file is 2026-04-06. Records are ingested in batches; same-day or subsequent filings may not yet be captured. UnitedHealth Group's most recent graph-linked record in this corpus dates to June 2025 — supplemental source monitoring recommended.*